Aclarion Partners with Northwestern Medicine for CLARITY Trial
Northwestern Medicine is a global leader in clinical trial research, including spine treatments.
CLARITY is a randomized study focusing on enhancing surgical outcomes and cost-effectiveness for chronic low back pain through Nociscan.
Nociscan aspires to establish itself as the benchmark in pinpointing sources of low back pain using MR Spectroscopy (MRS) and Augmented Intelligence (AI).
Aclarion, a healthcare technology innovator, is excited to announce Northwestern Medicine as the first location for its pivotal CLARITY trial. This initiative aims to illustrate Nociscan's significance in improving surgical results and economic efficiency for patients suffering from chronic low back pain.
"Northwestern Medicine exemplifies leadership in conducting pivotal clinical studies. The institution led over 6,900 clinical trials with an impressive count of 372,561 participants recently," said Alpesh Patel, MD. As a prominent figure and Co-Director at Northwestern’s Center for Spine Health, he expressed enthusiasm about joining Aclarion’s groundbreaking randomized trial focused on assessing the efficacy of Nociscan in surgical outcomes related to low back pain caused by disc issues.
The CLARITY trial, fully funded, will be under the guidance of Dr. Nicholas Theodore from Johns Hopkins University, serving as the principal investigator. This comprehensive, multi-center study will include 300 patients preparing for surgical solutions targeting one or two levels of discogenic low back pain. Importantly, every participant will undergo Nociscan evaluation prior to their surgery, facilitating a 1:1 ratio in randomized surgeon treatment that could be either blinded or unblinded to Nociscan.
Brent Ness, CEO of Aclarion, stated: "Launching the CLARITY trial with such a prestigious establishment as Northwestern Medicine, along with Dr. Alpesh Patel, gives us a unique opportunity to validate our technology. My prior experiences with clinical trials in cardiology taught me the value of credible trials in promoting cloud-based augmented intelligence platforms. We aim to measure metrics diligently to provide all stakeholders with evidence supporting the use of Nociscan in addressing chronic low back pain."
With chronic low back pain affecting approximately 266 million individuals worldwide, this healthcare dilemma emphasizes the need for innovative solutions. Aclarion’s Nociscan is pioneering as the first evidence-supported Software as a Service (SaaS) solution specifically designed to assist doctors in differentiating non-painful from painful discs in the lumbar region. This tool objectively measures chemical biomarkers tied to disc pain, which may enhance surgical results significantly.
The trial also stands to evaluate several outcomes, focusing on patient experiences and recovery processes. Information for those interested in the CLARITY trial can be accessed via their official website.
About Nociscan and Its Technology
Nociscan employs cutting-edge Magnetic Resonance Spectroscopy (MRS) combined with augmented intelligence to provide insights into spinal health. The platform operates through a cloud-based system that receives data from MRI imaging, interpreting the information to elucidate potential pain sources. This innovative approach not only aids healthcare professionals in treatment planning but also promises improved patient outcomes.
Through meticulous data processing, Nociscan aims to deliver clarity where conventional diagnostic methods may fall short, promoting better health management strategies for those affected by chronic low back pain.
Looking Ahead: The Impact of the CLARITY Trial
The collaboration with Northwestern Medicine marks a major milestone for Aclarion as it seeks to advance the clinical understanding of back pain treatments through evidence-based research. As they embark on this journey, their goal is to bring significant improvements to treatment pathways and patient care.
With a commitment to ongoing innovation, Aclarion looks forward to shedding light not just on the treatment of spine-related issues but on optimizing healthcare delivery and operational efficiencies across the sector.
Frequently Asked Questions
What is the purpose of the CLARITY trial?
The CLARITY trial aims to evaluate the effectiveness of Nociscan in enhancing surgical outcomes and reducing costs for patients with chronic low back pain.
Who is leading the CLARITY trial?
The trial is led by Dr. Nicholas Theodore from Johns Hopkins University, alongside a team from Northwestern Medicine.
How many participants will be involved in the CLARITY trial?
Approximately 300 patients will participate, all scheduled for surgery related to discogenic low back pain.
What technology does Nociscan use?
Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and AI algorithms to help physicians determine sources of low back pain noninvasively.
What are the expected outcomes of the trial?
The primary outcome measures the change in back pain levels after treatment, with secondary measures also focusing on various surgical outcomes and patient recovery metrics.
